A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Ipilimumab (Primary) ; Neoantigen DNA vaccine MedImmune/Washington University School of Medicine (Primary) ; Nivolumab (Primary) ; Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- 18 Sep 2018 Planned End Date changed from 5 Sep 2023 to 14 Sep 2023.
- 18 Sep 2018 Planned primary completion date changed from 5 Oct 2021 to 14 Oct 2021.
- 05 Sep 2018 Planned End Date changed from 31 Aug 2023 to 5 Sep 2023.